Did not receive funding from sponsor

This study is a prospective, randomized-controlled, non-blinded, multi-center, pilot trial to compare standard-of-care left ventricular assist device (LVAD) unloading plus heart failure (HF) medications reverse-remodeling management versus hemodynamics-guided LVAD unloading with use of the wireless monitoring system CardioMEMS plus HF medications reverse-remodeling management.

LVADs are being increasingly used in end-stage heart failure patients as a bridge to transplant (BTT) or as a destination therapy (DT). Although LVAD recipients are considered to be optimally unloaded with speed optimizations following LVAD implantation, re-hospitalizations due to HF recurrence are far from negligible. Recent studies have reported that at least 35% of hospital readmissions post-LVAD implantation are due to HF exacerbations, volume status changes or other cardiac causes (arrhythmias etc.). This suggests that patients are being sub-optimally unloaded and/or taking inadequate medical therapy and probably this decreases the chances for potential reverse remodeling and myocardial recovery. Moreover, a recent study demonstrated that cardiac dimensions obtained from echocardiography do not adequately reflect the degree of mechanical unloading of the heart. It has also shown strong evidence that pulmonary artery (PA) pressures monitoring can be reliably used to assess the pulmonary capillary wedge pressure (PCWP) and left ventricular end-diastolic pressure (LVEDP).

Symptomatic heart failure exacerbation requiring hospital admission may lie at the end of a spectrum of worsening hemodynamics that are unable to be detected before the manifestation of symptoms and limits the potential for myocardial recovery. Therefore, it is proposed that repeatedly adjusting LVAD pump flow speed and tailoring standard HF medications depending on the patient's PA pressure acquired from the CardioMEMS device can optimize pressure and volume unloading and promote reverse cardiac remodeling and recovery.

Clinical experience with LVAD support has shown that a subset of LVAD patients can experience reverse cardiac remodeling and significant improvement of myocardial function suggesting that LVAD-induced mechanical unloading of the failing heart may be a plausible therapeutic strategy aiming at myocardial recovery and device removal. These explanted patients have shown "myocardial plasticity" in clinical studies and that they can be responsive and sensitive to load changes. These patients will be carefully monitored to prevent increased load and wall stress to drive again the detrimental spiral of cardiac remodeling and HF recurrence, which appears to be the case in at least one third of LVAD patients after device weaning. Along the same lines, the results from another clinical study showed a significant and large reduction in hospitalization for HF patients who were managed with CardioMEMS. Therefore, further improvement of patients' HF management will depend mainly on better identification and pro-active management of their fluid and hemodynamic status. It is proposed that chronically adjusting HF medications using CardioMEMS-guided hemodynamic assessment in patients who have weaned from LVAD support could improve long-term durability of cardiac improvement after LVAD weaning.

Inclusion Criteria:

• Severe clinical HF resistant to intensive medical therapy and requiring LVAD implantation
• Left ventricular ejection fraction <=25% and cardiomegaly at time of LVAD implantation
• Non-ischemic etiology of HF
• Undergone LVAD implantation within prior 4 weeks or planned for LVAD implant
• History of HF < 5 years
• Body Mass Index <=35 kg/m^2
• Pulmonary artery branch diameter between 7 - 15 mm
• Female subjects of childbearing age with negative urine or serum pregnancy test and agreeing to use reliable mechanical or hormonal form of contraception during study

Exclusion Criteria:

• Evidence of active acute myocarditis confirmed by histology
• History of previous cerebrovascular accident resulting in significant fixed motor deficit, limiting ability to perform exercise testing
• Implanted mechanical aortic and/or mitral valve(s) and/or right heart valve(s)
• Aortic valve closure
• Hypertrophic obstructive cardiomyopathy or sarcoidosis
• Left ventricular end-diastolic diameter below normal (restrictive cardiomyopathy)
• Irreversible multi-organ failure
• Diagnosis of psychiatric disease, irreversible cognitive dysfunction or poor psycho-social issues likely to impair compliance with study protocol
• Any condition that could limit survival to less than 2 years
• History of cardiac or other organ transplant
• Contraindicated to anti-coagulation, antiplatelet therapy, or diagnosis of coagulation disorders
• Require acute or chronic renal replacement therapy within 3 months prior to enrollment
• Participation in any other clinical investigations involving another Mechanical Circulating Support device or HF-related drug
• Active infection
• History of recurrent (>1) pulmonary embolism or deep vein thrombosis
• Unable to tolerate right heart catheterization
• Implantation of cardiac re-synchronization therapy < 3 months before enrollment
• Congenital heart disease
• Hypersensitivity or allergy to aspirin and/or clopidogrel